<DOC>
	<DOCNO>NCT00003941</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . Peripheral stem cell transplant may allow doctor give high dos chemotherapy kill cancer cell . It yet know whether chemotherapy peripheral stem cell transplant effective chemotherapy alone . PURPOSE : This randomized phase III trial study well combination chemotherapy work give peripheral stem cell transplant compare combination chemotherapy alone treat men previously untreated germ cell cancer .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Peripheral Stem Cell Transplant Treating Men With Previously Untreated Germ Cell Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy standard cisplatin , etoposide , ifosfamide ( VIP ) follow sequential high-dose VIP stem cell rescue versus bleomycin , etoposide , cisplatin ( BEP ) men previously untreated poor-prognosis germ cell cancer . - Compare acute late toxicity treatment regimens patient population . - Compare regimens term failure-free survival , response rate , overall survival patient . - Evaluate quality life patient . OUTLINE : This randomize , multicenter study . Patients stratify accord center , primary mediastinal germ cell tumor ( yes v ) , nonpulmonary visceral metastasis ( liver v bone v brain ) . Patients randomize one two treatment arm . - Arm I : Patients receive etoposide IV 1 hour follow cisplatin IV 1 hour day 1-5 bleomycin IV 30 minute day 2 , 8 , 15 . Treatment repeat every 3 week 4 course . - Arm II : Patients receive 1 course standard dose chemotherapy consist etoposide IV 1 hour follow cisplatin IV 1 hour ifosfamide IV 1 hour day 1-5 . Peripheral blood stem cell ( PBSC ) harvest around day 12-15 . Patients also receive daily filgrastim ( G-CSF ) subcutaneously begin day 6 continue PBSC collection complete . After day 21 , patient receive high-dose chemotherapy consist etoposide IV 1 hour follow cisplatin IV 1 hour , ifosfamide IV 1 hour day -6 -2 . PBSCs infuse day 0 . Patients receive daily G-CSF subcutaneously begin day 1 continue day 19 blood count recover . Treatment repeat every 3 week 3 course absence disease progression unacceptable toxicity . Quality life assess chemotherapy , 6 month , 2 year treatment . Patients follow monthly 1 year , every 2 month 1 year , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 222 patient ( 111 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Mediastinal Neoplasms</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven germ cell cancer Nonseminoma OR Combined seminoma nonseminoma Poor prognosis ( nonseminoma ) : Testis/retroperitoneal primary AND One follow poor tumor marker AFP great 10,000 iu/L HCG great 50,000 iu/L LDH great 10 time upper limit normal OR Nonpulmonary visceral metastasis ( i.e. , liver , bone , brain ) OR Mediastinal primary PATIENT CHARACTERISTICS : Age : 16 50 Sex : Male Performance status : WHO 03 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) AST great 2 time ULN Renal : Creatinine clearance least 60 mL/min ( unless due obstructive uropathy correctable nephrostomy ) Other : No malignancy except basal cell skin cancer No neuropathy No serious illness medical condition No psychological , familial , sociological , geographical condition would prevent compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : Concurrent radiotherapy brain metastasis allow Surgery : Concurrent surgery brain metastasis allow</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>mediastinal cancer</keyword>
	<keyword>testicular embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma</keyword>
	<keyword>testicular teratoma</keyword>
	<keyword>testicular yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma teratoma</keyword>
	<keyword>testicular embryonal carcinoma teratoma seminoma</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor</keyword>
	<keyword>testicular embryonal carcinoma yolk sac tumor seminoma</keyword>
	<keyword>testicular embryonal carcinoma seminoma</keyword>
	<keyword>testicular yolk sac tumor teratoma</keyword>
	<keyword>testicular yolk sac tumor teratoma seminoma</keyword>
	<keyword>testicular choriocarcinoma yolk sac tumor</keyword>
	<keyword>testicular choriocarcinoma embryonal carcinoma</keyword>
	<keyword>testicular choriocarcinoma teratoma</keyword>
	<keyword>testicular choriocarcinoma seminoma</keyword>
	<keyword>tumor metastatic brain</keyword>
	<keyword>liver metastasis</keyword>
	<keyword>bone metastasis</keyword>
</DOC>